5-Aminosalicylate (5-ASA) for inflammatory bowel disease (IBD)
https://libcat.nshealth.ca/en/permalink/chpams35397
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1483
- Available Online
- View Pamphlet
5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (5 p.) : digital, PDF file
- Subjects (MeSH)
- Inflammatory Bowel Diseases - drug therapy
- Crohn Disease - drug therapy
- Colitis - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Crohn's disease
- Colitis
- Abstract
- 5-aminosalicylate (5-ASA) is a medication often used to treat inflammatory bowel disease (IBD). It helps to controll active ulcerative colitis, or Crohn’s colitis and keep mild to moderate ulcerative colitis in remission (period of recovery). Topics include: what does 5-ASA do, which 5-ASA you should take, how to take 5-ASA, what other medications you can take, and how 5-ASA will help. The pamphlet also describes side effects and how long you will need to take 5-ASA.
- Notes
- Previous title: 5-Aminosalicylate (5-ASA)
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1483
Crohn's disease and ulcerative colitis
https://libcat.nshealth.ca/en/permalink/provcat21261
Saibil, Fred.
Canadian Medical Association.
(2nd rev. ed.)
--Toronto, ON:
Key Porter Books
, 2003.
- Call Number
- WI 522 S132c 2003
- Location
- Nova Scotia Hospital
- Halifax Infirmary
- Call Number
- WI 522 S132c 2003
- Author
- Saibil, Fred
- Corporate Author
- Canadian Medical Association
- Edition
- 2nd rev. ed.
- Place of Publication
- Toronto, ON
- Publisher
- Key Porter Books
- Date of Publication
- 2003
- Physical Description
- 224 p.
- Series Title
- Your personal health series
- ISBN
- 1552635430
- Subjects (MeSH)
- Crohn Disease - Popular Works
- Colitis, Ulcerative - Popular Works
- Inflammatory Bowel Diseases - Popular Works
- Format
- Book
- Location
- Nova Scotia Hospital
- Halifax Infirmary
- Copies
- 2
- Loan Period
- 3 weeks
Ulcerative proctitis
https://libcat.nshealth.ca/en/permalink/chpams35311
Nova Scotia Health Authority. GI Clinic.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1422
- Available Online
- View Pamphlet
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. GI Clinic
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (4 p.) : digital, PDF file
- Subjects (MeSH)
- Colitis, Ulcerative
- Inflammatory Bowel Diseases
- Subjects (LCSH)
- Ulcerative colitis
- Inflammatory bowel diseases
- Abstract
- Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
- Responsibility
- Prepared by: GI Clinic
- Pamphlet Number
- 1422
Vedolizumab (Entyvio) therapy
https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1623
- Available Online
- View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (11 p.) : digital, PDF file
- Subjects (MeSH)
- Gastrointestinal Agents
- Colitis, Ulcerative - drug therapy
- Crohn Disease - drug therapy
- Subjects (LCSH)
- Gastrointestinal agents
- Ulcerative colitis
- Crohn's disease
- Specialty
- Medications
- Abstract
- Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1623
